Why the study?
Patients with chronic Chagas cardiomyopathy-related HFrEF represent a neglected subpopulation requiring dedicated heart failure treatments, particularly in Latin America.
Does sacubitril/valsartan improve outcomes compared to enalapril in patients with chronic Chagas cardiomyopathy and HFrEF?
Does sacubitril/valsartan improve outcomes compared to enalapril in patients with chronic Chagas cardiomyopathy and HFrEF?
Answers are grounded in this paper and cite their sources.
Baseline data from the PARACHUTE-HF trial demonstrates that patients with Chagas cardiomyopathy-related HFrEF have a distinct clinical profile, emphasizing the need for dedicated treatments in this population.
Baseline characteristics of this study highlight the unique clinical profile of patients with CCC-related HFrEF, including the high proportion of women affected, lower rates of comorbidities (hypertension/diabetes) and higher prevalence of stroke and pacemaker implantation when compared with other non-CCC-related HFrEF studies. These findings reinforce the need for dedicated heart failure treatments in this neglected subpopulation, particularly in Latin America where Chagas disease remains a significant public health issue.
No takes yet. Share an insight, caveat, or question.
Echeverría et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: